Scalper1 News
Aerie Pharmaceuticals (AERI) stock rocketed as much as 41% in the stock market today after the company, which develops therapies for treating patients with eye diseases, reported upbeat phase 2b trial results for its experimental glaucoma drug Roclatan. Roclatan is an eyedrop treatment that can be administered on a once-daily basis. It is a combination of Aerie’s Rhopressa (phase 3 trial triple-action glaucoma drug candidate) and latanoprost, a Scalper1 News
Scalper1 News